

Resource Summary Report

Generated by [dkNET](#) on Sep 7, 2026

lentiCRISPR v2

RRID:Addgene_52961

Type: Plasmid

Proper Citation

RRID:Addgene_52961

Plasmid Information

URL: <http://www.addgene.org/52961>

Proper Citation: RRID:Addgene_52961

Insert Name: Cas9

Organism: Synthetic

Bacterial Resistance: Ampicillin

Defining Citation: [PMID:25075903](#)

Vector Backbone Description: Backbone Size:10000; Vector Backbone:Custom; Vector Types:Mammalian Expression, Lentiviral, CRISPR; Bacterial Resistance:Ampicillin

Comments: This plasmid is an updated version of the original lentiCRISPR (Addgene plasmid #49535) IMPORTANT: The primers suggestions listed above are for gene inserts that exist in the untouched vector. After you have inserted your gRNA, you should use hU6-F (5'-GAGGGCCTATTTCCCATGATT-3') or LKO.1 5'(5'-GACTATCATATGCTTACCGT-3') to sequence that region. Special note from the Zhang lab: We are constantly improving our CRISPR reagents. Please check <https://zlab.bio/> for the most up-to-date information.

Plasmid Name: lentiCRISPR v2

Record Creation Time: 20220422T222310+0000

Record Last Update: 20260905T075756+0000

Ratings and Alerts

No rating or validation information has been found for lentiCRISPR v2.

No alerts have been found for lentiCRISPR v2.

Data and Source Information

Source: [Addgene](#)

Usage and Citation Metrics

We found 3693 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Hu X, et al. (2026) Immune gene diversity and STING1 variants in shaping cancer immunity across different genetic ancestry populations. *Cell reports*, 45(2), 116882.

Daly J, et al. (2026) CRISPR activation screens map the genomic landscape of cancer glycome remodeling. *Cell genomics*, 6(4), 101139.

Chen B, et al. (2026) BRD4-mediated ER membrane contact creates functionally distinct mitochondrial subtypes. *Molecular cell*, 86(5), 917.

Uible EE, et al. (2026) Scaffolding-dependent CASP1 constrains excessive cell-intrinsic inflammatory signaling in leukemia. *Cell chemical biology*, 33(1), 59.

Li L, et al. (2026) Ubiquitination-directed cytosolic DNA degradation governs cGAS-STING-mediated immune response to DNA damage. *Cancer cell*.

Liu Y, et al. (2026) Discovery of MARK2 as a physiological kinase for PER2 in the mammalian clock. *Cell chemical biology*, 33(3), 379.

Shah A, et al. (2026) ZAP targets aberrant mRNA transcripts encoding proteins with defective signal peptides for degradation. *The EMBO journal*, 45(8), 2638.

Zeng B, et al. (2026) HE4 drives PD-L1 expression in myeloid cells via IFN- γ -JAK-STAT3 signaling to promote tumor immune evasion. *Cell reports. Medicine*, 7(4), 102691.

Su M, et al. (2026) FASN inactivation-induced progranulin (GRN) expression promotes lysosome-dependent cell death to suppress leukemogenesis. *Cell reports*, 45(3), 117042.

van Dinther M, et al. (2026) Decoding the Mechanism of Action of a Parasite TGF β antagonist Inspires the Creation of Cell-type-specific TGF β Modulators. *bioRxiv : the preprint server for biology*.

Xie A, et al. (2026) Citrate clearance is a major function of aconitase 2 in the canonical TCA cycle. *Cell*, 189(9), 2684.

Suzuki T, et al. (2026) Lysine lactylation regulates ATF4-mediated stress responses under glucose starvation in canine hemangiosarcoma. *Frontiers in veterinary science*, 13, 1734339.

Yue F, et al. (2026) Loss of ZNRF3/RNF43 unleashes EGFR in cancer. *eLife*, 13.

Cao Y, et al. (2026) Targeting the ferritinophagy-lysosome axis as a therapeutic vulnerability in gastroenteropancreatic neuroendocrine tumors. *Cell reports. Medicine*, 7(4), 102695.

Ren X, et al. (2026) CRISPR tiling deletion screens reveal functional enhancers and allelic compensation effects (ACE) on SIN3A transcription. *Nature communications*, 17(1).

Huo C, et al. (2026) Loss-of-function variants in ODAD1 disrupt ODA docking and induce actin cytoskeletal remodeling in primary ciliary dyskinesia. *Cell discovery*, 12(1).

Liu X, et al. (2026) Claudins interact with LILRB immune inhibitory receptors to promote myeloid immunosuppression in cancer. *Science immunology*, 11(118), eadt7832.

Ramesh PS, et al. (2026) Inactivation of the RB1 and PTPN14 tumor suppressors cooperatively enables the carcinogenic activity of the human papillomavirus E7 oncoprotein. *bioRxiv : the preprint server for biology*.

Cheng L, et al. (2026) p53 safeguards chemical reprogramming of human somatic cells toward pluripotency. *Cell*, 189(12), 3541.

Wang X, et al. (2026) Tissue-selective COPII modulator SEC16B aggravates cardiovascular disease by promoting lipid export. *The EMBO journal*, 45(11), 3731.